- Conditions
- Acute Kidney Injury
- Interventions
- Nitric Oxide, Placebo
- Drug · Other
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 505–528
of 6,437
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Infection Due to Resistant Organism
- Interventions
- Fecal Microbiota Transplant (FMT), Bowel preparation, Stool or perirectal swab sampling, Fasting
- Biological · Procedure · Other
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Urolithiasis, Kidney Stones
- Interventions
- Technologist control of fluoroscopy, Surgeon control of fluoroscopy
- Procedure
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- 5 Years to 25 Years
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Kidney Failure, Acute, Kidney Failure, Chronic, Blood Platelet Disorders, Hemorrhage
- Interventions
- measuring Platelet Function Analyser-100 (PFA-100) platelet function before kidney biopsy
- Device
- Lead sponsor
- University of Mississippi Medical Center
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 1
- States / cities
- Jackson, Mississippi
- Conditions
- Chronic Kidney Disease (CKD) With Diabetes Mellitus (DM), CKD Stage 3, CKD Stage 4, CKD Stage 5, Diabetes Mellitus, Diabetic Kidney Disease
- Interventions
- PLAFOND diet
- Dietary Supplement
- Lead sponsor
- University of California, Irvine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 2
- States / cities
- Orange, California • Torrance, California
- Conditions
- Advanced Bladder Urothelial Carcinoma, Advanced Ureter Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Recurrent Bladder Urothelial Carcinoma, Recurrent Renal Pelvis Urothelial Carcinoma, Recurrent Ureter Urothelial Carcinoma, Recurrent Urethral Urothelial Carcinoma, Stage III Bladder Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8, Stage III Ureter Cancer AJCC v8, Stage III Urethral Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Renal Pelvis Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8, Stage IVA Bladder Cancer AJCC v8, Stage IVB Bladder Cancer AJCC v8, Unresectable Bladder Urothelial Carcinoma, Unresectable Renal Pelvis Urothelial Carcinoma, Unresectable Ureter Urothelial Carcinoma
- Interventions
- Atezolizumab, Biopsy, Biospecimen Collection, Computed Tomography, Glycosylated Recombinant Human Interleukin-7, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Positron Emission Tomography and Computed Tomography Scan
- Drug · Procedure · Biological + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 9
- States / cities
- Riverside, California • Tampa, Florida • Honolulu, Hawaii + 5 more
- Conditions
- Solid Tumor, Adult, Advanced Solid Tumor, Head and Neck Cancer, Breast Cancer, Colon Cancer, Pancreatic Cancer, Gastric Cancer, Esophageal Cancer, Prostate Cancer, Uterine Cancer, Cervix Cancer, Ovarian Cancer, Kidney Cancer, Bladder Cancer, Thyroid Cancer, Melanoma, Sarcoma, Advanced Cancer, Metastatic Cancer, Refractory Cancer, Non Small Cell Lung Cancer, Merkel Cell Carcinoma
- Interventions
- SNS-101 (anti-VISTA), Cemiplimab
- Drug
- Lead sponsor
- Sensei Biotherapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Aurora, Colorado • Louisville, Kentucky + 7 more
- Conditions
- Kidney Transplant Recipients
- Interventions
- Varivax®
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 2 Years to 21 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2001
- U.S. locations
- 4
- States / cities
- Birmingham, Alabama • Boston, Massachusetts • Ann Arbor, Michigan + 1 more
- Conditions
- Nephrotic Syndrome in Children
- Interventions
- Corticosteroids
- Drug
- Lead sponsor
- Wayne State University
- Other
- Eligibility
- 1 Year to 18 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Living Donor Nephrectomy
- Interventions
- Not listed
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 720 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2018
- U.S. locations
- 7
- States / cities
- Tucson, Arizona • Iowa City, Iowa • Portland, Maine + 4 more
- Conditions
- Lupus Nephritis
- Interventions
- Ianalumab
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 348 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2035
- U.S. locations
- 1
- States / cities
- Orchard Park, New York
- Conditions
- Chronic Kidney Disease, Acute Kidney Injury
- Interventions
- 75 mg / 6 mL VFI™
- Device
- Lead sponsor
- FAST BioMedical
- Industry
- Eligibility
- 19 Years to 75 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Kidney Stones
- Interventions
- Percutaneus nephrolithotomy (PCNL)
- Procedure
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- Not listed
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Low-grade Upper Tract Urothelial Carcinoma
- Interventions
- Nadofaragene Firadenovec
- Drug
- Lead sponsor
- Ferring Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 8
- States / cities
- Scottsdale, Arizona • Santa Monica, California • Jacksonville, Florida + 4 more
- Conditions
- Renal Transplant Failure and Rejection
- Interventions
- Siplizumab, Rabbit anti-thymocyte globulin
- Drug
- Lead sponsor
- Nefro Avillion Clinical Development, LLC
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 11
- States / cities
- Sacramento, California • Tampa, Florida • Atlanta, Georgia + 8 more
- Conditions
- Dietary Modification, Kidney Diseases, Chronic
- Interventions
- Usual protein and phosphorus diet, Low protein and phosphorus diet, Very low protein and phosphorus
- Behavioral
- Lead sponsor
- Johns Hopkins Bloomberg School of Public Health
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 840 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1988 – 2016
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Breast Cancer, Renal Cell Carcinoma
- Interventions
- IPI-549 (eganelisib), Atezolizumab, nab-paclitaxel, Bevacizumab
- Drug
- Lead sponsor
- Infinity Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 24
- States / cities
- Chandler, Arizona • Tucson, Arizona • Fullerton, California + 20 more
- Conditions
- Anemia
- Interventions
- methoxy polyethylene glycol-epoetin beta [Mircera]
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 137 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2005
- U.S. locations
- 6
- States / cities
- Los Angeles, California • San Jose, California • Boston, Massachusetts + 3 more
- Conditions
- Type 2 Diabetes, End Stage Renal Disease
- Interventions
- Placebo, Sitagliptin
- Drug
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years to 70 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Kidney Cancer
- Interventions
- motexafin gadolinium, sunitinib malate, comparative genomic hybridization, gene expression analysis, mutation analysis, polymorphism analysis, immunohistochemistry staining method, iodine I-124 girentuximab, laboratory biomarker analysis, pharmacological study, adjuvant therapy, neoadjuvant therapy, therapeutic conventional surgery
- Drug · Genetic · Other + 1 more
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Renal Cell Carcinoma
- Interventions
- Pazopanib
- Drug
- Lead sponsor
- SCRI Development Innovations, LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 17
- States / cities
- San Francisco, California • Fort Myers, Florida • Lakeland, Florida + 14 more
- Conditions
- Melanoma, Metastatic Kidney Cancer
- Interventions
- Interleukin-2 (IL-2)
- Drug
- Lead sponsor
- Loma Linda University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 2
- States / cities
- Beaumont, California • Loma Linda, California
- Conditions
- Elderly; Renal Insufficiency
- Interventions
- Computer-Assisted Decision Support
- Procedure
- Lead sponsor
- Indiana University
- Other
- Eligibility
- Not listed
- Enrollment
- 1,350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma
- Interventions
- PDR001, LCL161, Everolimus, Panobinostat, QBM076, HDM201
- Biological · Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 298 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 9
- States / cities
- Santa Monica, California • Baltimore, Maryland • Boston, Massachusetts + 6 more